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Background: Equine neuroaxonal dystrophy/equine degenerative myeloencephalopathy (eNAD/EDM)
is a neurodegenerative disorder affecting genetically predisposed foals maintained on an α-tocopherol
(α-TOH) deficient diet. Currently no antemortem diagnostic test for eNAD/EDM is available.
Hypothesis: Because α-TOH deficiency is associated with increased lipid peroxidation, it was
hypothesized that F2-isoprostanes (F2IsoP), F4-neuroprostanes (F4NP) and oxysterols derived
from free radical oxidation would be increased in the cerebrospinal fluid (CSF) and neural tissue
of eNAD/EDM affected horses and could serve as potential biomarkers for disease.
Animals: Isoprostane Study A: 14 Quarter horse foals (10 healthy foals and 4 eNAD/EDM affected
foals) at 1 and 6 months of age. Isoprostane Study B: 17 eNAD/EDM affected and 10 unaffected
horses ≥ 1-4 years of age. Oxysterol study: eNAD/EDM affected (n = 14, serum; n = 11, CSF;
n = 10, spinal cord [SC]) and unaffected horses 1-4 years of age (n = 12, serum; n = 10, CSF;
n = 7, SC).
Procedures: Cerebrospinal fluid [F2IsoP] and [F4NP] were assessed using gas chromatography-
negative ion chemical ionization mass spectrometry. Serum, CSF, and cervical SC [oxysterols]
were quantified using high performance liquid chromatography mass spectrometry. Results
were compared with respective α-TOH concentrations.
Results: Spinal cord [7-ketocholesterol], [7-hydroxycholesterol], and [7-keto-27-hydrocholes-
terol] were higher in eNAD/EDM horses whereas [24-ketocholesterol] was lower. No significant
difference was found in CSF [F2IsoP] and [F4NP], serum [oxysterols] and CSF [oxysterols]
between eNAD/EDM affected and unaffected horses. No correlation was found between
[F2IsoP], [F4NP], or [oxysterols] and respective [α-TOH].
Conclusions and Clinical Importance: In the SC, targeted markers of cholesterol oxidation were
significantly increased in horses with eNAD/EDM.
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Abbreviations: α-TOH, α-tocopherol; CI, confidence interval; CSF, cerebrospinal fluid; CYP, cytochrome P450; EDM, equine degenerative myeloencephalopathy;
eNAD, equine neuroaxonal dystrophy; EtOH, ethanol; F2IsoP, F2-isoprostanes; F4NP, F4-neuroprostanes; HPLC–APCI–MS/MS, high-performance liquid
chromatography–atmospheric pressure chemical ionization–tandem mass spectrometry; HPODE, hydroperoxy octadecadionoates; LC/MS, liquid chromatography/
mass spectrometry; LXR, liver X receptor; MDA, malondialdehyde; PUFA, polyunsaturated fatty acid; QH, Quarter Horse; RRR-α-TP, natural (or -d) α-tocopherol; SC,
spinal cord; SRM, selective reaction monitoring; TBAR, thiobarbituric acid reactivity; UHPLC–MS/MS, ultra-high performance liquid chromatography tandem mass
spectrometry; VitE, vitamin E
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1 | INTRODUCTION
Equine neuroaxonal dystrophy/equine degenerative myeloencephalo-
pathy (eNAD/EDM) is a neurologic condition that develops in geneti-
cally predisposed foals maintained on an α-tocopherol (α-TOH)
deficient diet.1,2 The disease appears to develop during the first year
of life3 and, in humans, there is strong evidence that the developing
nervous system is particularly at risk from α-TOH deficiency.4 The
underlying genetic cause remains unknown. Although α-TOH defi-
ciency in the cerebrospinal fluid (CSF) may be supportive of the diag-
nosis in younger horses (ie, <6 months of age),5 no definitive
antemortem diagnostic test currently is available. Decreased CSF
α-TOH concentrations in horses > 6 months of age may not be spe-
cific for eNAD/EDM.
The term vitamin E (vitE) encompasses a closely related family of
8 fat soluble naturally occurring compounds. Of these forms, α-TOH
most consistently prevents lipid peroxidation in vitro6 and in vivo.7,8
Biomarkers of lipid peroxidation often are assessed as indicators of
oxidative damage. Potential biomarkers include F2-isoprostanes
(F2IsoP), formed by oxidation of arachidonic acid and F4-
neuroprostanes (F4NP) from docosahexaenoic acid.
9 The measure-
ment of lipid peroxidation products is more reliable than the detection
of reactive oxygen species, reactive nitrogen species, and other active
oxidants.10
Lipid peroxidation products have various biological functions
in vivo such as regulating gene expression and cell signaling.11,12 In
eNAD/EDM affected horses, we recently identified upregulation of
specific genes targeted by a nuclear transcription factor, the liver X
receptor (LXR).13 The natural ligands for LXR activation are oxyster-
ols.14,15 Preliminary evaluation of eNAD/EDM affected horses identi-
fied a trend toward increased spinal cord (SC) 7-ketocholesterol and
7-hydroxycholesterol concentrations.13 These 2 oxysterols result from
autooxidation of cholesterol and oxidation of 7-dehydrocholesterol by
cytochrome P450 7A1 (CYP7A1; 7-alpha-hydroxylase).16
We hypothesized that measures of lipid peroxidation, including
F2IsoP, F4NP, and oxysterols would be significantly increased in the
CSF of eNAD/EDM affected horses. Additionally, we hypothesized
that the same oxysterol markers would be increased in SC tissue of
eNAD/EDM affected horses. The purpose of our study was to deter-
mine the concentrations of these biomarkers in eNAD/EDM affected
horses to potentially provide an antemortem diagnostic tool while fur-
ther investigating the etiology of the disease.
2 | MATERIALS AND METHODS
2.1 | Animals
2.1.1 | Isoprostane study A: Foal samples
For repeat measurements of F2IsoP and F4NP at 1 and 6 months of
age, 14 Quarter horse foals were used as previously described
(Table 1).5 These included 4 foals that developed eNAD/EDM during
the first year of life, which was confirmed on postmortem examination
at 1.5 years, and 10 healthy control foals that were maintained in the
same environment and fed an identical α-TOH deficient diet. Post-
mortem evaluation of the brain and SC tissue from eNAD animals
indicated histologic lesions typical of eNAD, namely chromatolytic
neurons and spheroid development that were especially prominent in
the lateral accessory cuneate, medial cuneate, and gracile nuclei.
Serum and CSF samples were collected as previously described.5 All
protocols were approved by the UCD Institutional Animal Care and
Use Committee (Protocol # 15866).
2.1.2 | Isoprostane study B: Adult samples
Over a period of 8 years, samples from 19 postmortem-confirmed
eNAD/EDM and 16 unaffected horses were collected (Supporting
Information Table S1). All horses were donated by owners for the pur-
poses of the study and were between 1 and 4 years of age. Biologic
samples (ie, serum, CSF, and SC tissue) were available on subsets of
eNAD/EDM affected and unaffected horses (Table 1 and Supporting
Information Table S1) and collected immediately before (serum) or
after (CSF, SC tissue) euthanasia. A moderate phenotype (eNAD) or
severe phenotype (eNAD/EDM) was diagnosed using histologic
lesions as previously described.2 Unaffected horses were euthanized
for reasons other than neurologic disease and subclinical eNAD was
excluded by histologic evaluation of the central nervous system.
2.1.3 | Oxysterol study
Samples from n = 14 (serum), n = 11 (CSF), and n = 10 (SC) eNAD/
EDM affected and n = 12 (serum), n = 10 (CSF), and n = 7
(SC) unaffected horses ages 1–4 years were available for oxysterol
quantification (Table 1 and Supporting Information Table S1). Spinal
cord sections were collected at the level of C1 as previously
described.13
TABLE 1 Sample sizes used for assays in this study
Analysis Age Analytes Sample
Horses
#Affected #Unaffected
Isoprostane Study A Repeated samples 1 and 6 mo F2-isoprostane and F4-neuroprostanes CSF 4 10
Isoprostane Study B 1–4 y F2-isoprostane and F4-neuroprostanes CSF 17 10
Oxysterol 1–4 y Cholesterol and oxysterols Serum 14 12
Oxysterol 1–4 y Cholesterol and oxysterols CSF 11 10
Oxysterol 1–4 y Cholesterol and oxysterols SC 10 7
For a full list of individual horses, refer to Supporting Information Table S1.
Abbreviations: CSF, cerebrospinal fluid; SC, spinal cord; mo, months; y, years.
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2.2 | Sample collection and storage
Cerebrospinal fluid (10–12 mL) was aliquoted into plastic light-
protected vials on ice and centrifuged at 4C (2000g for 15 minutes)
within 1 hour of collection. Supernatant was aliquoted 1 mL at a
time into precooled cryovials, immediately flash frozen in liquid
nitrogen and maintained at −80C until analysis. Serum samples
were collected from an IV catheter after removal of 6 mL of hepa-
rinized blood. Serum samples were processed in an identical manner
as CSF and frozen in 1 mL aliquots. For F2IsoP, F4NP, and oxysterol
quantification, samples were shipped to the respective laboratories
overnight on dry ice.
2.3 | α-TOH concentrations
For isoprostane Study A, α-TOH concentrations were assessed in
serum and CSF from foals at 1 and 6 months of age as previously
described.5 In Isoprostane Study B and oxysterol studies, α-TOH con-
centrations were assessed in serum (n = 19, eNAD/EDM affected;
n = 8, unaffected), CSF (n = 15, eNAD/EDM affected; n = 7, unaf-
fected), and SC tissue (n = 5, eNAD/EDM affected; n = 6, unaffected)
as previously described (Supporting Information Table S1).13
2.4 | F2-isoprostane and F4-neuroprostane
concentrations
F2-isoprostane (F2-IsoP, also referred to as 8-iso-PGF2α) and F4-NP
concentrations were assessed in CSF from horses in Study A at
1 and 6 months of age and in Study B at the time of euthanasia
(1–4 years of age). Quantification of F2IsoP and F4NP was per-
formed using a gas chromatography-negative ion chemical
ionization-mass spectrometry (GC-NICI-MS) approach employing
stable isotope dilution as previously described.17 The limit of detec-
tion for both assays was 1 pg.
2.5 | Cholesterol and oxysterol concentrations
Selected oxysterol concentrations were assessed based on preliminary
data indicating detectable concentrations in biologic samples.13 Serum
7-ketocholesterol, 7-hydroxycholesterol, 24-hydroxycholesterol, and 4β-
hydroxycholesterol; CSF 7-ketocholesterol and 24-epoxycholesterol; and
SC tissue 7-ketocholesterol, 7-hydroxycholesterol, 24-hydroxychole-
sterol, 24-ketocholesterol, 7-keto-27-hydrocholesterol, and 7–27-dih-
ydroxycholesterol concentrations were quantified.
2.5.1 | Materials
Liquid chromatography/mass spectrometry (LC/MS) grade solvents
(methylene chloride, chloroform, methanol, water, formic acid) were
purchased from Thermo Fisher Scientific (Thermo Fisher Scientific,
Waltham, Massachusetts). The d7-7-ketocholesterol was prepared as
reported previously.18 Two-hundred proof ethanol (USP Specification;
Decon Laboratories, King of Prussia, Pennsylvania), potassium hydrox-
ide (ACS certified; Thermo Fisher Scientific, Waltham, Massachusetts),
and sodium chloride (ACS certified; Thermo Fisher Scientific, Wal-
tham, Massachusetts) were used.
2.5.2 | Lipid extraction from tissues and fluids
Before lipid extraction, the internal standards, d7-7-ketocholesterol
(500 ng), d6-24-epoxycholesterol (500 ng), and d7-cholesterol (2.5 μg)
were added to each sample. For SC tissue, the tissues were homoge-
nized in Folch solution (4 mL, chloroform : methanol = 2 : 1) by a
blade homogenizer. For serum (100 μL), 4 mL of Folch solution was
added directly to each sample. Sodium chloride aqueous solution
(0.9%, 1 mL) then was added, and the resulting mixture was briefly
vortexed and centrifuged for 5 minutes. The lower organic phase was
recovered and dried at room temperature using a SpeedVac (Thermo
Fisher Scientific, Waltham, Massachusetts), and then re-dissolved in
methylene chloride (1 mL for tissue samples and 500 μL for CSF sam-
ples). For serum samples, extracts were dried under SpeedVac and the
dried samples then were reconstituted in 2 mL 2.5% KOH in 90% eth-
anol (EtOH) and incubated in a water bath at 55C for 55 minutes.
Another lipid extraction was performed on the solution from the base
hydrolysis and the extracts were dried under speed vacuum (Savant
SpeedVac, Thermo Fischer Scientific, Waltham, Massachusetts). Each
sample was reconstituted in methylene chloride (500 μL).
2.5.3 | High-performance liquid chromatography–
atmospheric pressure chemical ionization–tandem mass
spectrometry (HPLC–APCI–MS/MS) analyses of sterols and
oxysterols
Analysis of cholesterol and oxysterols was performed by ultra-HPLC
tandem mass spectrometry (UHPLC–MS/MS) using a triple quadru-
pole mass spectrometer (API 4000, Sciex, Framingham, Massachu-
setts) equipped with APCI. For analysis, an appropriate amount of
sample was transferred to a LC vial, dried under a stream of argon, and
reconstituted in 90% methanol with 0.1% formic acid (for oxysterol
analysis of SC tissue, 50 μL was reconstituted in 200 μL; for serum,
100 μL to 50 μL and for CSF, 100 μL to 50 μL). For cholesterol analysis,
20 μL was reconstituted in 200 μL for SC tissue, serum, and CSF.
Reverse-phase chromatography was performed under the following
conditions: C18 column (1.7 μm, 100 mm by 2.1 mm; Kinetex, Phe-
nomenex, Torrance, California); flow rate, 0.4 mL/min and elution sol-
vent, 90% methanol with 0.1% formic acid. Mass spectroscopy
conditions were nebulizer current, 3 mA; curtain gas, 10 psi; collision
gas, high; ion source gas, 20 pounds per square inch; entrance
potential, 10 V; collision energy, 25 V; declustering potential, 80 V;
collision cell exit potential, 20 V and temperature, 300C. For MS
analysis, selective reaction monitoring (SRM) was employed to monitor
the dehydration process of the ion [M + H]+ or [M + H-H2O]
+ as
described previously.13 The internal standard, d7-7-ketocholesterol,
was used to quantify the analytes 7-ketocholesterol, 4β-hydroxycho-
lesterol, and 7-hydroxycholesterol. d6-24-epoxycholesterol was used
to quantify 24-epoxycholesterol, 24-ketocholesterol, and
24-hydroxycholesterol; and, d7-cholesterol was used to quantify cho-
lesterol. Selective reaction monitoring mass transitions were d7-
7-ketocholesterol m/z 408.3 ! 390.3; d6-24-epoxycholesterol m/z
389.3 ! 371.3; 7-ketocholesterol, m/z 401.3 ! 383.3;
7-hydroxycholesterol, 4β-hydroxycholesterol, and 24-hydroxyc-
holesterol, m/z 385.3 ! 367.3; 24-epoxycholesterol and
24-ketocholesterol m/z 383.3 ! 365.3; d7-cholesterol m/z 376.3 !
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376.3; cholesterol m/z 369.3 ! 369.3. All concentrations were nor-
malized to cholesterol concentrations for quantification.
2.6 | Statistical analyses
2.6.1 | Isoprostane study A
A repeated measures 2-way ANOVA with Sidak's multiple compari-
sons was performed on F2IsoP concentrations. Because all F4NP
results were below the limit of detection at 6 months of age, a Mann-
Whitney test was used to compare values at 1 months of age.
2.6.2 | Isoprostane study B and oxysterol analyses
Data for each metabolite were analyzed for normality using a Shapiro-
Wilk test. Normally distributed data were analyzed using an unpaired
T-test with Welch's correction and non-normally distributed data with
a Mann-Whitney test. Correction for multiple testing was performed
at a false discovery rate of 0.1 within each sample subset.
2.6.3 | Correlation with age and α-TOH concentrations
Correlations of each metabolite with age and corresponding α-TOH
concentrations (serum, CSF and SC tissue) were performed using a
Pearson correlation for normally distributed data and a Spearman's
rank correlation for non-normally distributed data. Analyses were per-
formed using commercial software (GraphPad Prism7, La Jolla, Califor-
nia). Values are reported as mean ± SD and P < .05 was considered
significant.
3 | RESULTS
3.1 | F2-isoprostane and F4-neuroprostane
concentrations
3.1.1 | Isoprostane study A
In the foal population (1–6 months of age), no effect of disease
(P = .42) or age (P = .92) was found on CSF F2IsoP. The F4NP were
below the limit of detection in n = 2 eNAD/EDM affected and n = 3
unaffected foals at 1 months of age. No significant effect of disease
was found on CSF F4NP (P = .91).
3.1.2 | Isoprostane study B
A total of n = 17 eNAD/EDM affected (6 geldings, 2 stallions, 9 mares)
and n = 10 unaffected (2 geldings and 8 mares) samples were avail-
able for analysis of CSF F2IsoP and F4NP from adult horses (Table 1
and Supporting Information Table S1). No correlation of CSF F2IsoP
concentrations with age was found (R2 = 0.09) and no significant dif-
ference in age between experimental groups was found (eNAD/
EDM = 2.09 ± 1.03 years, unaffected = 2.77 ± 1.13 years; P = .12).
No significant effect of disease on CSF F2IsoP in horses aged ≥ 1–4
years (P = .93) was identified. All CSF F4NP were below the limit of
detection.
3.1.3 | Correlation with CSF α-TOH
For both Studies A and B, no significant correlation was found
between CSF F2IsoP and CSF α-TOH concentrations (R2 = 0.12,
P = .22, and R2 = 0.003, P = .82, respectively).
3.2 | Cholesterol and oxysterol concentrations
3.2.1 | Serum
Serum samples were available from n = 14 eNAD/EDM affected
(6 geldings, 2 stallions, 6 mares) and n = 12 unaffected
(3 geldings, 1 stallion, 8 mares) horses. No correlation of serum
7-ketocholesterol, 7-hydroxycholesterol, 24-hydroxycholesterol, and
4β-hydroxycholesterol concentrations with age was found and no sig-
nificant difference in age between experimental groups (eNAD/
EDM = 1.93 ± 0.96 years, unaffected = 2.37 ± 1.43 years; P = .37)
was identified. In serum, no effect of disease on serum
7-ketocholesterol (P = .23), 7-hydroxcholesterol (P = .32),
24-hydroxycholesterol (P = .53), or 4β-hydrocholesterol (P = .16) con-
centrations was found.
3.2.2 | Correlation with serum α-TOH
Serum α-TOH concentrations were available from n = 17 of the
26 samples (n = 12 eNAD/EDM and n = 5 unaffected horses, Sup-
porting Information Table S1). No correlation was identified between
any serum oxysterol assessed and serum α-TOH concentrations.
3.2.3 | CSF
A total of n = 11 eNAD/EDM affected (4 geldings, 2 stallions, 5 mares)
and n = 10 unaffected (3 geldings, 7 mares) horses were available for
analysis of CSF oxysterols. No correlation of CSF 7-ketocholesterol or
24-epoxycholesterol concentrations was found with age and no sig-
nificant difference in age between experimental groups (eNAD/
EDM = 1.73 ± 0.72 years, unaffected = 2.4 ± 1.05 years; P = .11)
was identified. In CSF, nonsignificantly (P = .07) increased
7-ketocholesterol concentrations were observed in eNAD/EDM
affected horses (Supporting Information Fig. S1). No effect of disease
on CSF 24-epoxycholesterol concentrations was found (P = .99).
3.2.4 | Correlation with CSF α-TOH
Cerebrospinal fluid α-TOH concentrations were available from n = 16
of the 21 samples (n = 11 eNAD/EDM and n = 5 unaffected horses).
No correlation was found between any CSF oxysterol and CSF α-TOH
concentrations.
3.2.5 | Spinal cord
Spinal cord samples were available from n = 10 eNAD/EDM affected
(4 geldings, 1 stallion, 5 mares) and n = 7 unaffected (2 geldings, 2 stal-
lions, 3 mares). No correlation of SC 7-ketocholesterol,
7-hydroxycholesterol, 24-hydroxycholesterol, 24-ketocholesterol, and
7,27-dihydroxycholesterol concentrations was found with age. A sig-
nificant negative correlation was observed between age and 7-keto-
27-hydroxycholesterol concentrations (Spearman r = −0.02
(confidence interval −0.73-0.04, P = .03). No significant difference in
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age was found between experimental groups (eNAD/
EDM = 1.35 ± 0.34 years, unaffected = 1.18 ± 0.25 years; P = .48).
Spinal cord 7-ketocholesterol (P = .002), 7-hydroxycholesterol
(P = .0007), and 7-keto-27-hydroxycholesterol (P = .03) concentrations
were significantly higher in eNAD/EDM affected horses (Figure 1A-C)
whereas 24-ketocholesterol was significantly lower (P = .02; Figure 1D),
even after accounting for multiple testing. No effect of disease on SC
24-hydroxycholesterol (Figure 1E) and 7,27-dihydroxycholesterol con-
centrations was identified. The majority (16/17) of SC tissue
7,27-dihydroxycholesterol concentrations were undetectable at the limit
of detection across the sample set.
3.2.6 | Correlation with CSF α-TOH
Cerebrospinal fluid α-TOH concentrations were available from n = 9
of the 17 samples (n = 3 eNAD/EDM and n = 6 unaffected horses).
No correlation was found between any SC oxysterol and SC α-TOH
concentrations.
4 | DISCUSSION
Markers of lipid peroxidation, including F2IsoP, F4NP, and oxysterols,
did not significantly differ in serum and CSF of eNAD/EDM
affected and unaffected horses. However, in SC tissue, targeted
markers of cholesterol oxidation, including 7-ketocholesterol,
7-hydroxycholesterol, and 7-keto-27-hydroxycholesterol were signifi-
cantly increased with eNAD/EDM. These particular oxysterols are
formed by reactive oxygen species-mediated oxidation of cholesterol
(Figure 2).16 7-Hydroxycholesterol consists of both 7α-
hydroxycholesterol, which is produced by CYP7A1 and free radical
oxidation, and 7β-hydroxycholesterol, formed by free radical oxida-
tion. Although CYP7A1 is not typically expressed in mammalian SC tis-
sue, we recently identified significant upregulation of this transcript in
eNAD/EDM affected horses.13 It is therefore possible that the
increased SC 7-hydroxycholesterol concentrations are because of a
combination of increased 7α-hydroxycholesterol from free radical oxi-
dation and CYP7A1 enzymatic activity and that increased 7β-
hydroxycholesterol is a consequence of free radical oxidation.
Increases in 7-ketocholesterol and its metabolite, 7-keto-
27-hydroxycholesterol, support further free radical oxidation of cho-
lesterol in SC tissue of eNAD/EDM affected horses (Figure 2).
The main mechanism for removing cholesterol from the brain is
enzymatic conversion of cholesterol to 24(S)-hydroxycholesterol
through CYP46A1 (Figure 2). A shift toward non-enzymatic, free-
radical mediated oxidation of cholesterol in the SC tissue of eNAD/
EDM affected horses (Figure 1E) indicates that oxidative stress may
contribute to disease pathogenesis. Alpha-TOH prevents lipid peroxi-
dation6 and therefore the associated α-TOH deficiency observed with
eNAD/EDM may directly lead to increased cholesterol oxidation in
the central nervous system. However, no direct correlation was
observed between SC α-TOH and oxysterol concentrations. We previ-
ously found that although serum, CSF and hepatic α-TOH concentra-
tions are significantly lower in eNAD/EDM affected horses and highly
correlated, SC tissue α-TOH concentrations did not differ and were
FIGURE 1 Spinal cord (A) 7-ketocholesterol, (B) 7-hydroxycholesterol, (C) 7-keto-27-hydroxycholesterol, (D) 24-ketocholesterol, and
(E) 24-hydroxycholesterol concentrations from eNAD/EDM affected and unaffected horses. Spinal cord 7-ketocholesterol, 7-hydroxycholesterol,
and 7-keto-27-hydroxycholesterol concentrations were significantly higher in eNAD/EDM affected horses while 24-ketocholesterol concentra-
tions were significantly lower. Data as min to max, with box extending from 25th to 75th percentiles and line representing the median. *P < .05,
**P < .01, ***P < .001
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not correlated with serum concentrations.13 Therefore, although the
pathology associated with eNAD/EDM is confined to the central ner-
vous system and CSF appears to be an appropriate sample to use for
assessment of α-TOH deficiency, SC tissue α-TOH concentrations
may not reflect the deficiency to the same extent. This may be
because of variable lipid concentrations in SC tissue, because lipid has
the highest concentration of α-TOH.19 In addition, in the horse, cho-
lesterol may be oxidized to oxidation products not included in our
analysis.
The finding of increases in SC 7-ketocholesterol and
7-hydroxycholesterol concentrations in eNAD/EDM affected horses
agrees with results reported previously. Our previous study identified
increased expression of LXR-responsive transcripts, including CYP7A1
and APOE, in the SC tissue of eNAD/EDM affected horses.13 The liver
X receptor is a nuclear transcription factor that requires activation by
binding of an oxysterol ligand. The main ligands of LXR include 24(S)-
hydroxycholesterol, 24,25-epoxycholesterol, 22-hydroxycholesterol,
20-hydroxycholesterol and 27-hydroxycholesterol.20 Of these, only
24-hydroxycholesterol was quantified in the current study and found
to not be increased in the SC tissue of eNAD/EDM affected horses.
Therefore, our findings may represent downstream consequences
after LXR activation rather than evidence of the initial ligand
activation.
24-Ketocholesterol was significantly decreased in the SC tissues
of eNAD/EDM affected horses. Although a negative correlation was
observed with age and 24-ketocholesterol, similar to reports in other
species,21 no significant difference in age was found between dis-
eased and healthy groups. 24-ketocholesterol is produced by
CYP46A1 from desmosterol (Figure 2).22 The enzyme CYP46A1 also
is responsible for converting cholesterol to 24(S)-hydroxycholesterol,
which was lower, but not significantly, in eNAD/EDM affected horses
(Figure 1E), potentially providing further support of decreased
CYP46A1 activity. A similar phenomenon was observed by our group
in mice deficient in tocopherol (alpha) transfer protein (Ttpa–/–). These
mice develop a postnatal sensory neurodegeneration like that
observed in eNAD/EDM.21 In wild-type mice, concentrations of
24(S)-hydroxycholesterol significantly increase in the SC tissue with
age, suggesting adequate CYP46A1 activity. In contrast, concentra-
tions of 24(S)-hydroxycholesterol do not increase with age in Ttpa–/–
mice. Therefore, the enzymatic removal of cholesterol in SC tissue
may be altered both in Ttpa–/– mice and eNAD/EDM affected horses
during postnatal development. Because various cholesterol products
differ in lipophilicity and therefore are eliminated differentially across
the blood brain barrier; this situation may contribute to the patho-
physiology of α-TOH deficient neurodegeneration.
Paradoxically, despite higher SC 7-ketocholesterol concentra-
tions in eNAD/EDM affected horses, CSF 7-ketocholesterol
concentrations were non-significantly lower (Supporting
Information Fig. S1). Like cholesterol, oxysterols can only be elimi-
nated directly from cells to lipophilic acceptors, mediated by
specific membrane lipid transporters, including ATP-binding
cassette, subfamily A, member 1 (ACBA1); ATP-binding cassette,
subfamily G, member 1 (ABCG1); and, scavenger receptor BI
(SRBI).23 Alterations in these proteins could interfere with
oxysterol elimination from cells. Therefore, these are strong candi-
date genes for eNAD/EDM. Alternatively, altered oxysterol con-
centrations in neuronal plasma membranes may alter basic
membrane properties.24 Although lower CSF 7-ketocholesterol
concentrations in eNAD/EDM affected horses’ warrants further
evaluation in a larger sample set, this finding may suggest an
altered transport mechanism for 7-ketocholesterol removal in
eNAD/EDM.
FIGURE 2 Mechanisms of cholesterol production and generation of oxysterols (purple font) via enzymatic and nonenzymatic oxidation. Specific
oxysterols were detectable in equine serum (yellow circle), CSF (teal circle) and SC tissue (pink circle). Cyp, cytochrome P450; ROS, reactive
oxygen species; 7-KC, 7-ketocholesterol; 7-KC,27-OHC, 7-keto-27-hydroxycholesterol; 7β-OHC, 7β-hydroxycholesterol; 7β,27-diOHC,
7β,27-dihydroxycholesterol; 7α-OHC, 7α-hydroxycholesterol; 7,27-diOHC, 7α,27-dihydroxycholesterol; 4β-OHC, 4β-hydroxycholesterol; 24(S)-
OHC, 24(S)-hydroxycholesterol; 24-KC, 24-ketocholesterol; 24-epoxychol, 24-epoxycholesterol
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F2IsoP, F4NP, and oxysterols are only a subset of markers used to
assess lipid peroxidation in biologic systems. Additional markers,
including malondialdehyde, which is one of the products formed from
decomposition of certain primary and secondary lipid peroxidation
products, and thiobarbituric-acid-reactivity have been used in other
disease processes as markers of lipid peroxidation.9 However, these
markers are not recommended for use in biologic systems without
correlative data from other indices of fatty peroxide formation and
decomposition.25 Therefore, isoprostanes and oxysterols were
selected for evaluation in our study. Limitations of our study
include inability to perform all assays on all sample types and the lack
of matched serum, CSF, and SC tissue results by individual. Addition-
ally, because of limited sample availability, F2IsoP and F4NP were not
evaluated in SC tissue. It is therefore possible that, similar to
targeted oxysterols, F2IsoP and F4NP may be increased in SC tissue of
eNAD/EDM affected horses without increased concentrations in
the CSF.
In conclusion, targeted markers of cholesterol oxidation were
significantly increased in the SC tissue of eNAD/EDM affected
horses. Although serum and CSF biomarkers of eNAD/EDM
were not identified, the mechanism of neurodegeneration was
further elucidated. Enzymatic removal of cholesterol in SC
tissue may be altered in eNAD/EDM affected horses during
postnatal development, which could interfere with neuronal
membrane signaling mechanisms, resulting in subsequent
neurodegeneration.
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